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Consensus on the Need for a Hierarchical List of
Patient-reported Pain Outcomes for Metaanalyses of
Knee Osteoarthritis Trials: An OMERACT Objective
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ABSTRACT. Objective. Although protocol registration for systematic reviews is still not mandatory, reviewers
should be strongly encouraged to register the protocol to identify the methodological approach,
including all outcomes of interest. This will minimize the likelihood of biased decisions in reviews,
such as selective outcome reporting. A group of international experts convened to address issues
regarding the need to develop hierarchical lists of outcome measurement instruments for a particular
outcome for metaanalyses.
Methods. Multiple outcome measurement instruments exist to measure the same outcome.
Metaanalysis of knee osteoarthritis (OA) trials, and the assessment of pain as an outcome, was used
as an exemplar to assess how Outcome Measures in Rheumatology (OMERACT), the Cochrane
Collaboration, and other international initiatives might contribute in this area. The meeting began with
formal presentations of background topics, empirical evidence from the literature, and a brief intro-
duction to 2 existing hierarchical lists of pain outcome measurement instruments recommended for
metaanalyses of knee OA trials. 
Results.After discussions, most participants agreed that there is a need to develop a methodology for
generation of hierarchical lists of outcome measurement instruments to guide metaanalyses. Tools
that could be used to steer development of such a prioritized list are the COSMIN checklist
(COnsensus-based Standards for the selection of health status Measurement Instruments) and the
OMERACT Filter 2.0. 
Conclusion. We list meta-epidemiological research agenda items that address the frequency of
reported outcomes in trials, as well as methodologies to assess the best measurement properties (i.e.,
truth, discrimination, and feasibility). (First Release May 1 2015; J Rheumatol 2015;42:1971–5;
doi:10.3899/jrheum.141384)
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The Outcome Measures in Rheumatology (OMERACT) inter-
national consensus initiative has successfully developed core
outcome sets for trials of many rheumatologic conditions, but
its expanding scope called for clarification and updating of its
underlying conceptual framework and working process1. The
selection of appropriate outcomes, and subsequently instru-
ments to measure these, is crucial when designing and inter-
preting clinical trials, to compare the effects of different
interventions directly in ways that minimize bias. 
Among patients with osteoarthritis (OA), the knee joint is
particularly important given its importance for ambulation and
thereby function of the individual. Loss of function is closely
related to pain and may be more important to the patient than
the actual radiographic signs of OA2,3. At the third OMERACT
conference (1996), a core domain set was developed for future
phase III trials of knee, hip, and hand OA, using a combination
of discussion and polling procedures. There was consensus that
the following 4 domains should be measured and reported in
all clinical trials: pain, physical function, patient global
assessment, and for studies of 1 year or longer, joint imaging4.
However, no consensus was reached on which measurement
instruments to apply. Consequently, in clinical trials (for
example, in patients with knee problems), pain is being
assessed using many different instruments5.
Systematic reviews of knee OA randomized trials are
crucial for making evidence-based decisions regarding
available therapies6,7,8. The preparation of a protocol for a
systematic review starts with a clear formulation of the
research question in the PICO search strategy framework9,
i.e., a clinically relevant or policy-relevant question that takes
into account Population, Intervention, Comparison, and
Outcomes — including both the benefit and harm of the inter-
vention being studied10. The choice of the outcome instru-
ment of interest for any given construct, to include in
metaanalyses, is generally based on clinical judgment.
Because outcomes on a specific domain (e.g., pain) can each
be measured using a range of different instruments, it is often
necessary to standardize assessments to a common scale
using the standardized mean difference3, before the outcomes
across trials can be combined in a metaanalysis.
To prevent bias and ensure transparency in reporting, it is
now considered mandatory (for leading journals) that clinical
trials be registered, and key protocol elements be made
publicly available prior to trial completion11. Despite this,
outcomes reported in published articles of trial results are
frequently incomplete and inconsistent with their protocol
where one is available12, which can lead to bias13 — perhaps
especially for serious adverse events14. Following this,
systematic reviewers may thereby further introduce bias into
their metaanalyses using such data, because any posthoc
evaluation can affect the findings of metaanalyses, either in
an optimistic or pessimistic direction. Therefore, the validity
of systematic reviews is potentially vulnerable if a trial has
considered several outcomes but reports only those giving
significant results and if the systematic review protocol has
not specified outcomes and the hierarchy of outcomes in
advance of its conduct15. Although protocol registration for
systematic reviews is still not mandatory16 except for
Cochrane and Campbell systematic reviews10, reviewers
should be strongly encouraged to prespecify and register all
critical issues in their protocol17. It follows that a published
or registered and publicly available protocol18 may help
restrict the likelihood of biased posthoc decisions in review
methods, such as selective outcome reporting19.
In addition to prespecification of (a hierarchy of) out-
comes in clinical trials and systematic reviews, consensus is
also needed on instruments that have been used to measure
these outcomes. The OMERACT Filter 2.0 explicitly
describes a comprehensive conceptual framework and a
recommended process to select outcomes (domains) and
develop core outcome measurement sets for rheumatology
trials20. To build on this work, a group of international experts
convened to address issues regarding the need to develop
hierarchical lists of outcome measurement instruments for
reporting these core outcomes in metaanalyses of clinical
trials, and to assess how OMERACT might contribute.
MATERIALS AND METHODS
The OMERACT Executive group identified the need to develop a deliberate
dialogue between groups interested in achieving consensus on outcomes and
outcome measurement instruments and to provide optimal evidence for
benefit and harms in systematic reviews of studies on chronic painful musculo-
skeletal conditions. This article describes results of a workshop evaluating the
hierarchy of pain-related continuous outcome measurement instruments
recommended for metaanalyses and systematic reviews of knee OA trials;
knee OA was selected as a prototype that can be used to develop a template
for hierarchies in other musculoskeletal conditions.
Topics for discussion underpinning the need for consensus on the need
for hierarchical lists on outcome measurement instruments for pain in
metaanalyses of knee OA trials were included. The formal introductory
presentations focused on specific issues, including relevant empirical
evidence related to the need for a hierarchical list of patient-reported pain
outcome measurement instruments.
RESULTS
The workshop participants were clinical epidemiologists,
clinicians, patients, biostatisticians, and the editor-in-chief of
the Cochrane Collaboration. One of the first tasks of the
workshop was to review the objectives to clarify any
outstanding issues among the 9 participants. The issues
identified for discussion included reporting bias and multi-
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plicity, as well as existing hierarchical lists of pain-related
outcome measurement instruments for metaanalyses.
Reporting Bias and Multiplicity in Metaanalyses
A synthesis of recent data on this topic was presented. The
group agreed that study publication and outcome reporting
biases are potential threats to the validity of metaanalysis. In
addition, metaanalyses of pain studies may include trials
measuring pain using more than 1 instrument, thereby intro-
ducing potential bias related to issues of multiplicity21.
Tendal, et al showed that the possible effect of multiple data
points in trial reports regarding measurement scales,
time-points, or intervention groups on metaanalysis results
varies greatly across metaanalyses21. Consequently, data in
trial reports might lead to biased decisions about which data
to include in metaanalyses. Individuals should be aware of
these biases as possibly making the readily available evidence
unreliable for decision making22. 
After the presentations, participants emphasized that it
would be valuable if a systematic review protocol specified
major outcomes in terms of core domains (e.g., pain and
physical function). A protocol should probably also address
potential reporting bias and multiplicity issues by prespecifying
a proposed hierarchy of potentially available measurement
instruments. Explicit consideration of the timepoint(s) for
measurement would also be preferable. One issue raised was
whether it was “a given” that metaanalyses are always
valuable. Most participants argued that the issues of clinical
heterogeneity (e.g., population, interventions, and compara-
tors) are important. Therefore metaanalysis is not always
feasible and should always be considered in the context of the
contributing studies23. However, because good systematic
reviews should build on the premise that selected trials fulfill
a specific PICO criterion (asking the same research ques-
tion)10, it should be possible to combine them, provided there
is some degree of clinical homogeneity. The heterogeneity
caused by different instruments measuring the same outcome
is, on the other hand, not an acceptable reason for excluding
evidence synthesis.
Another comment was that any proposed measurement
instrument hierarchy needs to be supported by the instru-
ments’ documented psychometric properties24, rather than
developed by simply using consensus based on available data
from the literature. All participants supported this notion and
indicated that, before developing a hierarchy, the psycho-
metric properties of the proposed individual instruments have
to be taken into consideration. That led the group to the
conceptual question of whether the “simple visual analog
scale (VAS)” is valid25, and/or whether it needs/deserves a
degree of psychometric reconsideration.
Existing Hierarchical Lists of Pain-related Outcome
Measurement Instruments for Metaanalyses
Jüni, et al26 presented a hierarchical list of pain-related
continuous outcome measurement instruments recommended
for OA trials. It was suggested that the reported outcome of
the instrument highest on this list should be extracted to
minimize outcome reporting bias (Table 1)26. The list was
generated based on input from a small group of OA experts,
without any input from patients and without consideration of
available empirical data. Currently, this proposed hierarchy
is part of the preliminary default template suggested — but
not yet endorsed — by the Cochrane Musculoskeletal Group
(CMSG) editorial team regarding the selection and inclusion
of pain measurement instruments in summary of findings
tables for OA interventions.
Jüni, et al’s hierarchical list26 has since been followed by
another, as recommended by Juhl, et al27, who concluded that
choosing the instrument with the most favorable results for the
intervention from individual trials could lead to biased
estimates in metaanalyses. As a result, Juhl, et al recommended
a pragmatic hierarchy based on a prioritized list (Table 1). The
creation of this proposed hierarchy involved some degree of
empirical evidence on the responsiveness of pain instruments
derived from a systematic search conducted in the 20 highest
impact factor general and rheumatology journals27.
After the presentation, most participants agreed that a
hierarchy would be desirable, making it “mandatory” for
systematic reviewers to follow a prespecified list, rather than
having potential selection bias at the metaanalysis stage.
Among the participants there was agreement that neither of
the existing papers provided compelling data to support any
of the proposed hierarchies. A critical element of the discus-
sions identified was that empirical evidence for the frequent
use of any particular outcome instrument might not neces-
sarily imply good psychometric properties24. Thus we were
not able to achieve consensus on the “best approach” for
measuring pain outcomes for metaanalyses of knee OA trials.
The group was, however, supportive of using both lists (Table
1) as inspiration and a starting point for further research. Two
points of view were relevant from these discussions: (1)
preference was given to the continuing use of the Jüni, et al
hierarchy26 as a consequence of the present CMSG support10,
whereas (2) the recommended hierarchy from Juhl, et al has
the advantage of encouraging use of the validated Western
Ontario and McMaster Universities Arthritis (WOMAC)
Index28 — and thus indirectly also the Knee injury and
Osteoarthritis Outcome Score29,30 — over any VAS assess-
ments with unclear psychometric properties25.
Voting Results (Plenary)
After the individual workshops, a plenary session was held
and all meeting participants were asked to vote on 2 questions
related to a hierarchical list of pain instruments applicable for
metaanalyses:
(1) Do we need a hierarchical list of instruments for a
particular outcome within a particular domain for systematic
reviews to prevent selective data extraction?
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(2) Is determining the methodology to develop a hierarchical
list of instruments an important research question?
Out of 39 responders, 25 (64%) agreed that there is a need
for a hierarchical list of instruments to prevent selective data
extraction in metaanalyses and systematic reviews. From the
voting it was clear that this topic probably needed further
discussion as the number of participants who voted “Don’t
know” was similar to the proportion voting “No” [7 (18%)
in each group]. However, the attendees were less hesitant
when asked whether the methodology to develop such hier-
archical lists was an important research question: 90%
(35/39) voted “Yes” and the remaining 10% voted “No.”
By the end of the OMERACT premeeting, there was
consensus among the participants of the need to develop a
hierarchical list of outcome instruments for outcomes within
the pain domain for metaanalyses and systematic reviews.
Because choosing the most beneficial result from available
outcome measurement instruments from individual trials can
over/underestimate the effect compared with a systematic
approach21,22,31, developing a protocol for the metaanalysis
or systematic review and using a prioritized list will probably
aid reviewers in prespecifying endpoints. 
Other Aspects That Need to Be Addressed
The need for a hierarchical list of outcome instruments (to
avoid bias) apparently also applies to other critical features
of a systematic review, such as: (1) “How should the decision
on optimal trial duration be determined?”; (2) “Is there a
minimum sample size requirement?”; and (3) “Is there a
minimum baseline pain intensity/frequency, etc.?” 
Judging from the intensive discussions, the need for
hierarchies of instruments for available core outcome
measurement sets is likely to be relevant for any outcome in
any health condition for which systematic reviewers might
do evidence synthesis — not just pain21. This underlines the
potential use of the existing OMERACT core domain set for
guidance on possible endpoints4. It was also clear from the
discussions and the voting results, that determining the
methodology to develop hierarchical lists of instruments is
an important research question.
Research Agenda
Following these valuable discussions, we suggest the
following for working groups who want to propose hierar-
chical lists for outcome measurement instruments in
metaanalyses: 
• Combine meta-epidemiology32, i.e., evaluation of the
frequency of use of different instruments in the
published trial literature33;
• Examine the performance of systematic reviews of studies
on different instruments’ measurement properties24; and
• Consider the suggestion that, among outcomes
frequently reported in trials based upon meta-epidemi-
ology studies, those with the best measurement pro-
perties as assessed by frameworks such as “OMERACT
Filter 2.0”20 or the COSMIN (COnsensus-based
Standards for the selection of health status Measurement
Instruments) checklist34, would be ranked high on a
hierarchical list for selection of outcome measurement
instruments in metaanalyses. 
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Table 1. Previously suggested hierarchies of pain measurement instruments applicable for metaanalyses of knee osteoarthritis (OA). Modified from Jüni, et
al26: Best Pract Rheumatol 2006; and from Juhl, et al27: Arthritis 2012;136245.
Ranking Jüni, et al Juhl, et al
1 Global pain score WOMAC pain subscale (Likert/100 mm)
2 Pain on walking Pain during activity (VAS)
3 WOMAC OA index pain subscore Pain during walking (VAS)
4 Composite pain scores other than WOMAC Global knee pain (VAS)
5 Pain on activities other than walking (such as stair climbing) Pain at rest (VAS)
6 WOMAC global score SF-36 (bodily pain subscale)
7 Lequesne OA index global score HAQ (pain subscale)
Lequesne algofunctional index (pain subscale) 
AIMS (pain subscale)
Knee-Specific Pain Scale
McGill Pain Questionnaire (pain intensity)
ASES (pain subscale)
SES (Schmerzempfindungsskala)
8 Other algofunctional composite scores Pain at night (VAS)
Pain during activity (NRS)
Pain on walking (NRS)
No. painful days (days)
9 Patient’s global assessment
10 Physician’s global assessment
WOMAC: Western Ontario and McMaster Universities Osteoarthritis Index; VAS: visual analog scale; SF-36: Medical Outcome Study Short Form-36; AIMS:
Arthritis Impact Measurement Scale; ASES: American Shoulder and Elbow Surgeons Shoulder Score; HAQ: Health Assessment Questionnaire; NRS: numerical
rating scale.
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